A Phase IIIII Study Testing Remternetug to Prevent or Slow Alzheimers Disease Progression in Adults with Genetic Risk

What this Trial Is About

Researchers are evaluating remternetug, an investigational drug, to study its effects on asymptomatic individuals at risk for dominantly inherited Alzheimers disease DIAD caused by genetic mutations. The study aims to assess whether remternetug can prevent or reduce amyloid beta accumulation, a protein linked to Alzheimers progression, and to evaluate its impact on various disease biomarkers and safety. This research involves two stages Stage 1 focuses on amyloid beta changes, while Stage 2 examines downstream biomarkers related to disease progression compared to control groups. Participants will receive remternetug or a matching placebo as a subcutaneous injection every 12 weeks in a randomized, double-blind design. Following Stage 1, an open-label phase will begin after the last dose, allowing participants to receive remternetug openly. The study uses brain imaging, blood, and spinal fluid tests to monitor biomarker changes and treatment effects over time, with assessments scheduled up to 192 weeks. Participants are involved in regular visits for cognitive and clinical evaluations, brain scans using PET imaging, and collection of fluid samples to track biomarker changes. Researchers will closely monitor safety, tolerability, and cognitive measures throughout the study. The total participation duration extends over multiple years, with ongoing assessments to understand the drugs effect on disease progression and participant well-being.

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation